Januario Castro is an Oncology physician. OpenAlex indexes 238 publications with 9,856 citations (h-index 30); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 85259
Telephone
480-301-8000Provider last certified this registry record 25 Feb 2026.
Clinical trials
- Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)
Sponsor: Januario Castro, M.D.
- A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
Sponsor: University of California, San Diego
- Study of Repeat Intranodal Injections of Ad-ISF35
Sponsor: Januario Castro, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.1%PD-1 inhibitor30.9%Pembrolizumab52%Nivolumab48%Part B, office-administered≥19 patientsCD38-directed Cytolytic Antibody23.2%Daratumumab100%Part B, office-administered≥34 patients+ 6 more classes in this area
Metabolism & gastrointestinal
20%Other antiemetics16%Fosaprepitant100%Part B, office-administered≥28 patientsSerotonin-3 Receptor Antagonist2.9%Ondansetron hydrochloride50%Palonosetron hcl48%Ondansetron Hcl2%Part D + Part B≥45 patients+ 2 more classes in this area
Anti-infectives
3.8%Human Immunoglobulin G3.6%Immune globulin100%Part B, office-administered≥16 patientsShort-acting sulfonamides0.1%Sulfamethoxazole-Trimethoprim100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology – A comprehensive analysis of clinical trials
Critical Reviews in Oncology/Hematology
2025 - Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”